Enhanced heparosan biosynthesis in Corynebacterium glutamicum by systematic metabolic engineering and translation-level fine-tuning

Abstract

As a widely used anticoagulant, heparin is industrially produced chiefly via animal tissue extraction, which suffers from unstable supply and potential safety hazards. Heparosan shares a similar polysaccharide backbone with heparin and can be converted into heparin under mild enzymatic catalysis. In addition, heparosan exhibits favorable biocompatibility and non-immunogenicity, rendering its efficient, eco-friendly biosynthesis essential. In this study, we systematically engineered Corynebacterium glutamicum, a Generally Recognized as Safe (GRAS) microorganism, to synthesize heparosan via two complementary strategies. First, genome-scale modification was implemented to stably upregulate genes ugd, glmS, and ndk. The heparosan titer of recombinant strain Cg24 increased from 226.37 to 595.39 mg/L. Second, translation-level fine-tuning was implemented to modulate expression of individual genes within the kfiB-kfiC-kfiA cassette by constructing a high-coverage random ribosome binding site (RBS) library, which further lifted heparosan titer to 1161.37 mg/L. In fed-batch fermentation using a 5 L bioreactor with a two-stage growth-production regulation strategy, the recombinant strain Cg24-11 produced 5.36 g/L of heparosan, demonstrating its great potential for efficient heparosan biosynthesis. This combined modification strategy also provides valuable references for constructing high-efficiency cell factories for other complex compounds.

Graphical abstract

Keywords

Heparosan / Corynebacterium glutamicum / Systematic metabolic engineering / Translation-level fine-tuning / Fed-batch fermentation

References

[1] Baytas SN, Linhardt RJ. Advances in the preparation and synthesis of heparin and related products. Drug Discov Today, 2020, 25(12): 2095-2109

[2] Bertini S, Risi G, Guerrini M. Molecular weights of bovine and porcine heparin samples: comparison of chromatographic methods and results of a collaborative survey. Molecules. 2017

[3] Bitter T, Muir HM. A modified uronic acid carbazole reaction. Anal Biochem, 1962, 4(4): 330-334

[4] Chen JX, Liu W, Zhang M, et al. . Heparosan based nanocarrier for rapid intracellular drug delivery. J Controlled Release, 2015, 213: 54-55

[5] Chen XF, Chen R, Yu XX, et al. . Metabolic engineering of Bacillus subtilis for biosynthesis of heparosan using heparosan synthase from Pasteurella multocida, PmHS1. Bioprocess Biosyst Eng, 2017, 40(5): 675-681

[6] Chen YZ, Wan ZH, Li ZJ. Development of sucrose-utilizing Escherichia coli Nissle 1917 for efficient heparosan biosynthesis. Metabolites, 2025, 15(6): 410

[7] DeAngelis PL, White CL. Identification and molecular cloning of a heparosan synthase from Pasteurella multocida type D. J Biol Chem, 2002, 27797209-7213

[8] Deng C, Xin RJ, Li XJ, et al. . Optogenetic control of Corynebacterium glutamicum gene expression. Nucleic Acids Res, 2024, 52(22): 14260-14276

[9] Deng C, Xin RJ, Li XJ, et al. . Corynebacterium glutamicum for microbial production of chitin oligosaccharides using modular engineering. Food Bioeng, 2025, 4(2): 127-141

[10] Guerrini M, Beccati D, Shriver Z, et al. . Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol, 2008, 26(6): 669-675

[11] Hogwood J, Mulloy B, Lever R, et al. . Pharmacology of heparin and related drugs: an update. Pharmacol Rev, 2023, 75(2): 328-379

[12] Hu LT, Wang Y, Hu YX, et al. . Biosynthesis of non-sulfated high-molecular-weight glycosaminoglycans and specific-sized oligosaccharides. Carbohydr Polym, 2022, 295: 119829

[13] Hu S, Zhao LL, Hu LT, et al. . Engineering the probiotic bacterium Nissle 1917 as an efficient cell factory for heparosan biosynthesis. Enzyme Microb Technol, 2022, 158110038

[14] Hu S, Zhou SY, Wang Y, et al. . Coordinated optimization of the polymerization and transportation processes to enhance the yield of exopolysaccharide heparosan. Carbohydr Polym, 2024, 333121983

[15] Jiang XH, Zhang B, Cai X, et al. . Progress on the synthesis of bioengineered heparin as an alternative to animal-derived heparin active pharmaceutical ingredient. Carbohydr Polym, 2025, 368124099

[16] Jin P, Zhang LP, Yuan PH, et al. . Efficient biosynthesis of polysaccharides chondroitin and heparosan by metabolically engineered Bacillus subtilis. Carbohydr Polym, 2016, 140424-432

[17] Kitade Y, Okino S, Gunji W, et al. . Identification of a gene involved in plasmid structural instability in Corynebacterium glutamicum. Appl Microbiol Biotechnol, 2013, 97(18): 8219-8226

[18] Leroux M, Priem B. Chaperone-assisted expression of KfiC glucuronyltransferase from Escherichia coli K5 leads to heparosan production in Escherichia coli BL21 in absence of the stabilisator KfiB. Appl Microbiol Biotechnol, 2016, 100(24): 10355-10361

[19] Liu YF, Liu L, Chen JH, et al. . Effects of carbon sources and feeding strategies on heparosan production by Escherichia coli K5. Bioprocess Biosyst Eng, 2012, 35(7): 1209-1218

[20] Mengin-Lecreulx D, van Heijenoort J. Copurification of glucosamine-1-phosphate acetyltransferase and N-acetylglucosamine-1-phosphate uridyltransferase activities of Escherichia coli: characterization of the glmU gene product as a bifunctional enzyme catalyzing two subsequent steps in the pathway for UDP-N-acetylglucosamine synthesis. J Bacteriol, 1994, 176(18): 5788-5795

[21] Nehru G, Tadi SRR, Limaye AM, et al. . Production and characterization of low molecular weight heparosan in Bacillus megaterium using Escherichia coli K5 glycosyltransferases. Int J Biol Macromol, 2020, 160: 69-76

[22] Nehru G, Tadi SRR, Sivaprakasam S. Application of dual promoter expression system for the enhanced heparosan production in Bacillus megaterium. Appl Biochem Biotechnol, 2021, 193(8): 2389-2402

[23] Normile D. Arrival of deadly pig disease could spell disaster for China. Science, 2018, 361(6404): 741-741

[24] Pan YJ, Liu ZL, Wang P, et al. . Synthetic biology for heparin biomanufacturing. Bioresour Bioprocess, 2026, 13(1): 9

[25] Qi B, Zhang JN, Ma WL, et al. . Biosensor-assisted multitarget gene fine-tuning for N-acetylneuraminic acid production in with sole carbon source glucose. J Agric Food Chem, 2025, 73169793-9806

[26] Qiu LP, Ge L, Long MM, et al. . Redox-responsive biocompatible nanocarriers based on novel heparosan polysaccharides for intracellular anticancer drug delivery. Asian J Pharm Sci, 2020, 15(1): 83-94

[27] Rippe M, Stefanello TF, Kaplum V, et al. . Heparosan as a potential alternative to hyaluronic acid for the design of biopolymer-based nanovectors for anticancer therapy. Biomater Sci, 2019, 7(7): 2850-2860

[28] Schäfer A, Tauch A, Jäger W, et al. . Small mobilizable multi-purpose cloning vectors derived from the Escherichia coli plasmids pK18 and pK19: selection of defined deletions in the chromosome of Corynebacterium glutamicum. Gene, 1994, 145(1): 69-73

[29] Sheng LL, Cai YM, Li Y, et al. . Advancements in heparosan production through metabolic engineering and improved fermentation. Carbohydr Polym, 2024, 331: 121881

[30] Shi C, Wu TT, Li JP, et al. . Comprehensive landscape of heparin therapy for COVID-19. Carbohydr Polym, 2021, 254117232

[31] Shi ZZ, Ming Y, Li J, et al. . Production of chondroitin by Corynebacterium glutamicum through co-utilization of glucose and xylose from corn straw. Int J Biol Macromol, 2025, 327(Part1): 147392

[32] Shi ZZ, Ming Y, Li J, et al. . Engineering compartmentalized utilization of glycerol with glucose for high-level chondroitin production in Corynebacterium glutamicum. Carbohydr Polym, 2026, 378124946

[33] van der Meer JY, van den Kellenbach E, Bos LJ. From Farm to Pharma: An Overview of Industrial Heparin Manufacturing Methods. Molecules. 2017

[34] Wan ST, Liu X, Sun WT, et al. . Current advances for omics-guided process optimization of microbial manufacturing. Bioresour Bioprocess, 2023, 10130

[35] Wang ZY, Ly M, Zhang FM, et al. . E. coli K5 fermentation and the preparation of heparosan, a bioengineered heparin precursor. Biotechnol Bioeng, 2010, 1076964-973

[36] Wang Z, Dordick JS, Linhardt RJ. Escherichia coli K5 heparosan fermentation and improvement by genetic engineering. Bioeng Bugs, 2011, 2(1): 63-67

[37] Wang PP, Chi LL, Zhang ZQ, et al. . Heparin: an old drug for new clinical applications. Carbohydr Polym, 2022, 295119818

[38] Wei L, Zhao JH, Wang YR, et al. . Engineering of Corynebacterium glutamicum for high-level γ-aminobutyric acid production from glycerol by dynamic metabolic control. Metab Eng, 2022, 69134-146

[39] Wu ML, Sapin-Minet A, Gaucher C. Heparin, an active excipient to carry biosignal molecules: applications in tissue engineering-a review. Int J Biol Macromol, 2025, 312: 143959

[40] Xue Q, Wu RX, Yu J. Systematic optimization of fed-batch fermentation for enhanced heparosan production in engineered Corynebacterium glutamicum. Int J Biol Macromol. 2026

[41] Yang W, Frickenstein AN, Sheth V, et al. . Controlling nanoparticle uptake in innate immune cells with heparosan polysaccharides. Nano Lett, 2022, 22(17): 7119-7128

[42] Yu J, Zhang Y, Zhang H, et al. . Coupling optimization of cell growth cycle and key enzyme membrane localization for enhanced synthesis of high molecular weight heparosan by Corynebacterium glutamicum. Bioresour Bioprocess, 2025, 12(1): 61

[43] Zhang CY, Liu L, Teng LP, et al. . Metabolic engineering of Escherichia coli BL21 for biosynthesis of heparosan, a bioengineered heparin precursor. Metab Eng, 2012, 145521-527

[44] Zhang B, Zhou N, Liu YM, et al. . Ribosome binding site libraries and pathway modules for shikimic acid synthesis with Corynebacterium glutamicum. Microb Cell Fact, 2015, 1471

[45] Zhang Q, Yao R, Chen XL, et al. . Enhancing fructosylated chondroitin production in Escherichia coli K4 by balancing the UDP-precursors. Metab Eng, 2018, 47314-322

[46] Zhang YL, Wang Y, Zhou ZX, et al. . Synthesis of bioengineered heparin by recombinant yeast Pichia pastoris. Green Chem, 2022, 24(8): 3180-3192

[47] Zhao GH, Tang YQ, Li ZH, et al. . Engineering Corynebacterium glutamicum for efficient L-homoserine production. Bioresour Technol, 2025, 431132617

Funding

National Natural Science Foundation of China(32301214)

Fundamental and Interdisciplinary Disciplines Breakthrough Plan of the Ministry of Education of China(JYB2025XDXM509)

RIGHTS & PERMISSIONS

The Author(s)